← brief for 2026-09-03 · Slowing decline

Use of Pegmolesatide in Renal Anemia: Efficacy and Safety of Switching to Pegmolesatide in Non-dialysis CKD Patients Treated With rhuEPO or HIF-PHI

Key takeaways

A trial is starting on switching anemia treatment in kidney disease. About 160 people not yet on dialysis, already taking EPO shots or a HIF-PHI pill, will be randomly moved to a drug called pegmolesatide for 24 weeks, with 24 more weeks of follow-up. Low blood count is common in kidney disease and is a big cause of exhaustion. There are no results yet, this is only the plan.

Who did this work

Run by The First Affiliated Hospital of Dalian Medical University. Hongli Lin, M.D. (The First Affiliated Hospital of Dalian Medical University)
Sites: Poster

Source

Trial · ClinicalTrials.gov, CKD recruiting · 2026-09-02
https://clinicaltrials.gov/study/NCT06946394